Literature DB >> 34743281

Early Postoperative Patient-Reported Outcomes After Thoracoscopic Segmentectomy Versus Lobectomy for Small-Sized Peripheral Non-small-cell Lung Cancer.

Wei Dai1,2, Shuai Chang1, Cecilia Pompili3,4, Bin Qiu5, Xing Wei2, Yunfei Mu6, Rui Zhang7, Cheng Shen1, Qiuling Shi8, Qiang Li2, Zhong Wu9, Guowei Che10.   

Abstract

BACKGROUND: Patient-reported outcomes are critical for obtaining valuable patient insight into different surgical treatment options with comparable clinical outcomes. This study aimed to compare early postoperative patient-reported symptoms and functioning between thoracoscopic segmentectomy and lobectomy for small-sized (≤ 2 cm) peripheral non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: This study included 110 patients who underwent thoracoscopic segmentectomy or lobectomy for peripheral NSCLC ≤ 2 cm in a multicenter prospective longitudinal study (CN-PRO-Lung 1). Symptom severity, functional status, and short-term clinical outcomes were compared between the groups. Symptom severity and functional status were measured using the MD Anderson Symptom Inventory-Lung Cancer at baseline, daily post-surgery, and weekly post-discharge for up to 4 weeks. Both the proportion of moderate-to-severe scores and mean scores on a 0-10 scale were compared between the groups.
RESULTS: Overall, 48 and 62 patients underwent thoracoscopic segmentectomy and lobectomy, respectively. No significant between-group differences were found in the severity of the top five symptoms (coughing, shortness of breath, pain, fatigue, and disturbed sleep) or in the impairment of all six function items (work, walking, general activity, enjoyment of life, mood, and relations with others) during both the 6-day postoperative hospitalization and the 4-week post-discharge (all p > 0.05). Short-term clinical outcomes of postoperative hospital stay, operative time, drainage time, postoperative in-hospital oral morphine equivalent dose, and complication rate were also comparable (all p > 0.05).
CONCLUSIONS: In patients with peripheral NSCLC ≤ 2 cm, thoracoscopic segmentectomy and lobectomy might produce comparable symptom burden and functional impairment during the early postoperative period.
© 2021. Society of Surgical Oncology.

Entities:  

Mesh:

Year:  2021        PMID: 34743281     DOI: 10.1245/s10434-021-10946-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  2 in total

1.  [Effects of VATS Lobectomy, VATS Anatomic Segmentectomy, and Open Thoracotomy on Pulmonary Function of Patients with Non-small Cell Lung Cancer].

Authors:  Yanjiao Zhang; Yushun Gao
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-10-20

2.  [China National Lung Cancer Screening Guideline with Low-dose Computed 
Tomography (2018 version)].

Authors:  Qinghua Zhou; Yaguang Fan; Ying Wang; Youlin Qiao; Guiqi Wang; Yunchao Huang; Xinyun Wang; Ning Wu; Guozheng Zhang; Xiangpeng Zheng; Hong Bu; Yin Li; Sen Wei; Liang'an Chen; Chengping Hu; Yuankai Shi; Yan Sun
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-02-20
  2 in total
  4 in total

1.  ASO Author Reflections: Using Patient-Reported Outcomes to Compare Thoracoscopic Segmentectomy and Lobectomy.

Authors:  Wei Dai; Yunfei Mu; Shuai Chang; Zhong Wu; Guowei Che
Journal:  Ann Surg Oncol       Date:  2021-10-20       Impact factor: 5.344

2.  ASO Author Reflections: Comparison of Three Lymph Node Staging Systems for Prognostic Evaluation of Resected Gastric Adenocarcinoma.

Authors:  Keying Che; Jia Wei
Journal:  Ann Surg Oncol       Date:  2021-06-22       Impact factor: 5.344

Review 3.  Progress in three-dimensional computed tomography reconstruction in anatomic pulmonary segmentectomy.

Authors:  Zhe Wu; Zhangfeng Huang; Yi Qin; Wenjie Jiao
Journal:  Thorac Cancer       Date:  2022-05-18       Impact factor: 3.223

4.  Analysis of the Effect of Quality Nursing on Recovery after Thoracic Surgery.

Authors:  Yujing Zhou; Ming Xu
Journal:  Emerg Med Int       Date:  2022-10-07       Impact factor: 1.621

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.